Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics' SAB-142 receives FDA Fast Track designation for Stage 3 type 1 diabetes

Neutral Impact 3 of 5 product/contract Written later

SAB Biotherapeutics announced that the FDA granted Fast Track designation to SAB-142, an immunotherapy being developed for new-onset Stage 3 type 1 diabetes. The designation is intended to facilitate development and expedite review for serious conditions with unmet medical need, and the filing says SAB-142 is in a registrational Phase 2b study with topline data anticipated in 2H 2027.

Key points

  • FDA granted Fast Track designation to SAB-142 for new-onset Stage 3 type 1 diabetes, announced October 13, 2026
  • SAB-142 is being evaluated in the registrational Phase 2b SAFEGUARD study, with enrollment expected to be completed in Q4 2026
  • Topline data from the SAFEGUARD study are anticipated in 2H 2027
  • The filing does not disclose financial figures related to the designation

The filing

CompanySAB Biotherapeutics, Inc. (SABS)
Form8-K, current report
Filed with the SECOct 13, 2026, 8:36 AM ET
Accession number0001193125-26-419769

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.